for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

KAKEN PHARMACEUTICAL CO., LTD.

4521.T

Latest Trade

5,100.00JPY

Change

80.00(+1.59%)

Volume

92,500

Today's Range

5,070.00

 - 

5,140.00

52 Week Range

4,535.00

 - 

6,000.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5,020.00
Open
5,090.00
Volume
92,500
3M AVG Volume
2.21
Today's High
5,140.00
Today's Low
5,070.00
52 Week High
6,000.00
52 Week Low
4,535.00
Shares Out (MIL)
39.32
Market Cap (MIL)
225,564.10
Forward P/E
12.15
Dividend (Yield %)
3.05

Next Event

Q2 2020 Kaken Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Kaken Pharmaceutical says distribution agreement for Clenafin in Hong Kong and Macau

Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan

Kaken Pharmaceutical receives marketing approval for Jublia in S.Korea

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About KAKEN PHARMACEUTICAL CO., LTD.

KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in the production and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.

Industry

Biotechnology & Drugs

Contact Info

20F, Bunkyo Green Court Center Office

2-28-8, Honkomagome

+81.3.59775001

http://www.kaken.co.jp

Executive Leadership

Tetsuo Ohnuma

President, Representative Director

Hiroyuki Horiuchi

Managing Director, Chief Director of Sales

Jun Takaoka

Managing Director

Naoyuki Ishida

Executive Officer, Director of Human Resources

Jumpei Suzuki

Executive Officer, Director of Accounting

Key Stats

4.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (JPY)

2017

536.700

2018

470.540

2019

445.780

2020(E)

413.085
Price To Earnings (TTM)
10.50
Price To Sales (TTM)
2.44
Price To Book (MRQ)
1.60
Price To Cash Flow (TTM)
10.86
Total Debt To Equity (MRQ)
3.21
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
15.00
Return on Equity (TTM)
12.20

Latest News

Latest News

BRIEF-Valeant Announces Licensing Agreement With Kaken Pharma For Psoriasis Treatment

* ANNOUNCES LICENSING AGREEMENT WITH KAKEN PHARMACEUTICAL CO., LTD. TO DEVELOP AND COMMERCIALIZE NEW CHEMICAL ENTITY FOR PSORIASIS

BRIEF-Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan

* Says co signed an exclusive distribution agreement with Tai Tien Pharmaceuticals Co Ltd (Tai Tien), which is a subsidiary of Mitsubishi Tanabe Pharma Corporation, for the topical formulation for Onychomycosis "Clenafin/Jublia" (product) in Taiwan

BRIEF- Kaken Pharmaceutical to begin sale of Jublia in Korea

* Says its partner company Dong-A ST Co., Ltd. will begin the sale of Jublia, a topical formulation drug for Onychomycosis, in Korea, from June 1

BRIEF-Kaken Pharmaceutical receives marketing approval for Jublia in S.Korea

* Says product Jublia, topical formulation for Onychomycosis, has received marketing approval in South Korea

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up